Investing.com - U.S. stocks edged lower on Tuesday, as investors assessed a weaker-than-anticipated reading on consumer confidence and took some caution ahead of crucial quarterly ...
Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...
Meanwhile, Hims & Hers (NYSE: HIMS) warned that it may stop selling legal copies of a popular weight-loss drug made by Denmark's Novo Nordisk (NYSE: NVO ), sending shares in the U.S. telehealth firm ...
Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, ...
Investing.com - Hims&Hers (NYSE:HIMS) said on Monday that it may stop selling legal copies of a popular weight-loss drug made by Denmark's Novo Nordisk (NYSE:NVO), sending shares in the U.S.
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won't be selling it for much longer. Hims & Hers Health Inc.'s stock plunged last week when the Food ...
Fuse Vectors has raised $5.2 million of funding as it moves closer to commercialising its innovative new approach to ...
Around the world, progressive parties have come to see tight immigration restrictions as unnecessary, even cruel. What if ...
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...